In the cutthroat real-world market of selling pharmaceuticals, anything that's bad for your competition is probably good for you. In that sense, a recent Citizen's Petition filed with the FDA calling for the removal of Novo Nordisk's (NVO) Victoza from the market is certainly not a bad development for Amylin Pharmaceuticals (AMLN). Unfortunately, given the often over-heated debate and pancreatitis in GLP-1 drugs, this is not likely to have much real-world influence.
Please continue here:
Will Amylin Stand To Gain From A Citizen's Petition Challenging Victoza?
No comments:
Post a Comment